Literature DB >> 6086146

Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen.

R E Lanford, J S Butel.   

Abstract

An SV40-adenovirus 7 hybrid virus, PARA(cT), has been described that is defective for the nuclear transport of SV40 large tumor antigen. An SV40(cT) mutant was constructed using SV40 early and late region DNA fragments derived from PARA(cT) and wild-type SV40 respectively. The SV40(cT)-3 construct is defective for viral replication, but can be propagated in COS-1 cells. T antigen induced by SV40(cT)-3 is localized in the cytoplasm of infected cells. The cT mutation also inhibits the transport of wild-type T antigen; COS-1 cells lose their constitutive expression of nuclear T antigen after infection with SV40(cT)-3. Sequence analysis revealed that the cT mutation results in the replacement of a positively charged lysine in wild-type T antigen with a neutral asparagine at amino acid number 128, demonstrating that the alteration of a single amino acid is sufficient to abolish nuclear transport. Implications of the cT mutation on possible mechanisms for the transport of proteins to the nucleus are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086146     DOI: 10.1016/0092-8674(84)90415-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  197 in total

1.  Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals.

Authors:  M Arese; Y Chen; R Z Florkiewicz; A Gualandris; B Shen; D B Rifkin
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

2.  The RelA nuclear localization signal folds upon binding to IκBα.

Authors:  Carla F Cervantes; Simon Bergqvist; Magnus Kjaergaard; Gerard Kroon; Shih-Che Sue; H Jane Dyson; Elizabeth A Komives
Journal:  J Mol Biol       Date:  2010-11-19       Impact factor: 5.469

3.  What clinicians should know about SV40 large T antigen and nucleocytoplasmic transport.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2003-11       Impact factor: 4.599

4.  Baculovirus transregulator IE1 requires a dimeric nuclear localization element for nuclear import and promoter activation.

Authors:  Victoria A Olson; Justin A Wetter; Paul D Friesen
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Distal protein sequences can affect the function of a nuclear localization signal.

Authors:  M Gao; D M Knipe
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

Review 6.  Merkel cell carcinoma: a virus-induced human cancer.

Authors:  Yuan Chang; Patrick S Moore
Journal:  Annu Rev Pathol       Date:  2011-09-13       Impact factor: 23.472

7.  Nucleocytoplasmic distribution is required for activation of resistance by the potato NB-LRR receptor Rx1 and is balanced by its functional domains.

Authors:  Erik Slootweg; Jan Roosien; Laurentiu N Spiridon; Andrei-Jose Petrescu; Wladimir Tameling; Matthieu Joosten; Rikus Pomp; Casper van Schaik; Robert Dees; Jan Willem Borst; Geert Smant; Arjen Schots; Jaap Bakker; Aska Goverse
Journal:  Plant Cell       Date:  2010-12-21       Impact factor: 11.277

8.  Monoclonal antibody to a protein of the nucleus and mitotic spindle of mammalian cells. Localization and synthesis throughout the cell cycle.

Authors:  D D Newmeyer; B M Ohlsson-Wilhelm
Journal:  Chromosoma       Date:  1985       Impact factor: 4.316

9.  Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma.

Authors:  M M Lotz; C W Andrews; C A Korzelius; E C Lee; G D Steele; A Clarke; A M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Schwannoma-derived growth factor must be transported into the nucleus to exert its mitogenic activity.

Authors:  H Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.